Previous 10 | Next 10 |
2024-03-25 07:27:03 ET DENVER, Colo., Mar 25, 2024 ( 247marketnews.com )- Nkarta, Inc. (NASDAQ: NKTX ) stated, this morning, that it priced an underwritten offering of 21,010,000 shares of its common stock at a price of $10.00 per share and pre-funded warrants to purchase 3,000,031 ...
2024-03-25 07:26:02 ET More on Nkarta Nkarta's Strategic Advances In Cell Therapy For Autoimmune Disorders Nkarta: Possible Upside From H1 Update, If Positive Seeking Alpha’s Quant Rating on Nkarta Read the full article on Seeking Alpha For fur...
SOUTH SAN FRANCISCO, Calif., March 25, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced the pricing of an underwritten offering of 21,010,000 shares of its common stock at a price of $10.00 ...
A look at the top 10 most actives in the United States Fisker Inc. Class A (FSR) fell 4.2% to $0.1248 on volume of 179,379,334 shares Biolase Inc. (BIOL) rose 19.5% to $0.1793 on volume of 129,349,610 shares Direxion Daily Semiconductor Bear 3X Shares (SOXS) fell 0.6% to $3.22 on volume o...
2024-03-22 13:02:29 ET More on Mid-day movers & stocks. Veritone, Inc. (VERI) Q4 2023 Earnings Call Transcript Aemetis, Inc. (AMTX) Q4 2023 Earnings Call Transcript Aemetis, Inc. 2023 Q4 - Results - Earnings Call Presentation Aemetis surges after USCIS ap...
A look at the top 10 most actives in the United States Biolase Inc. (BIOL) rose 52.0% to $0.228 on volume of 76,448,685 shares Faraday Future Intelligent Electric Inc. (FFIE) rose 8.5% to $0.1476 on volume of 32,191,096 shares Nova Lifestyle Inc (NVFY) rose 121.6% to $4.1 on volume of 32,...
2024-03-22 09:00:03 ET Gil Blum from Needham issued a price target of $15.00 for NKTX on 2024-03-22 08:17:00. The adjusted price target was set to $15.00. At the time of the announcement, NKTX was trading at $12.98. The overall price target consensus is at $34.00 with hi...
2024-03-21 16:45:19 ET More on Nkarta Nkarta's Strategic Advances In Cell Therapy For Autoimmune Disorders Nkarta: Possible Upside From H1 Update, If Positive Seeking Alpha’s Quant Rating on Nkarta Historical earnings data for Nkarta Financial ...
First patient dosing on track for first half of 2024 in clinical trial of NKX019 in lupus nephritis using disease-tailored lymphodepletion Additional B-cell mediated autoimmune diseases under consideration for broader clinical investigation of NKX019 Pipeline realignment focuses...
X4 Pharmaceuticals Inc. (XFOR) is expected to report $-0.15 for Q4 2023 Li Ning Co., Ltd. ADR (LNNGY) is expected to report for Q4 2023 Xos Inc. (XOS) is expected to report $-2.4 for Q4 2023 PainReform Ltd. (PRFX) is expected to report for quarter end 2023-12-31 Muenchener Rueckve...
News, Short Squeeze, Breakout and More Instantly...
SOUTH SAN FRANCISCO, Calif., July 16, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced changes to its leadership team. Nadir Mahmood, Ph.D., will join Nkarta as President this month, sharing...
Patient screening underway in Ntrust-1, the first U.S.-based clinical trial of an engineered NK cell therapy for the treatment of lupus nephritis IND cleared for Ntrust-2, a clinical trial for NKX019 for the treatment of systemic sclerosis, myositis and vasculitis Clinical data ...